Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
AACR 2026: SingleCell Biotechnology targets oncology’s blind spot with functional single-cell profiling
Read how SingleCell Biotechnology’s AACR 2026 assay could reshape tumor heterogeneity research and oncology drug development.